Seeking Alpha
30 Sept 2026, 04:03 UTC · 2h ago
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Verdict
Headline takes no side. We score ZBIO +0.60 — strongly bullish.
- Expected · ZBIO
+0.60strongly bullish
−1 bearish0bullish +1More positive than 78% of ticker scores this week





